Solid Biosciences reported that its Chief Regulatory Officer, Jessie Hanrahan, sold 4,134 shares of the company's common stock on February 18, 2026. The transactions generated proceeds totaling $24,073 and were executed at a weighted average price of $5.8233 per share, with individual trades occurring between $5.23 and $6.14.
According to a Form 4 filed with the Securities and Exchange Commission, the disposition was carried out to satisfy withholding tax obligations that arose when previously granted restricted stock units vested. The filing also records that on February 13, 2026, Hanrahan acquired 8,125 shares of common stock and received 8,125 restricted stock units, each at a price of $0.00.
Beyond the insider transaction, Solid Biosciences outlined recent regulatory and clinical developments. The company said it has reached alignment with the U.S. Food and Drug Administration on the design for its Phase 3 clinical trial, IMPACT DUCHENNE, evaluating its candidate SGT-003. The agreed-upon trial will be randomized, double-blind, and placebo-controlled, and will enroll ambulant participants aged 7 to under 12 years.
Solid also reported progress in its ongoing Phase 1/2 INSPIRE DUCHENNE trial, noting that 33 participants have been dosed and that the therapy has been generally well tolerated in those treated.
In a separate program, the company said its investigational gene therapy SGT-212 received Orphan Drug designation from the FDA. Solid has dosed the first participant in the Phase 1b FALCON trial, which is studying SGT-212 in adults with Friedreich's ataxia and cardiac hypertrophy.
Following these regulatory and clinical updates, Citizens reiterated its Market Outperform rating on Solid Biosciences and kept a $15.00 price target. The firm cited the company's progress with the FDA on the Phase 3 trial design for SGT-003.
The insider sale, the equity granted to Hanrahan earlier in February, the FDA alignment on a Phase 3 design, the dosing updates across trials, and the orphan designation for SGT-212 together comprise the company developments disclosed in filings and company statements.
Readers should note that the Form 4 filing identifies the reason for the sale as tax withholding tied to vested restricted stock units and that the reported clinical and regulatory milestones were presented by the company as part of its program updates.